Eli Lilly Stock News

ImmunoGen Inc. shares jumped 7% in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly & Co. of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments. Camptothecins are a class of cancer drugs. Under the terms of the deal, ImmunoGen will receive $13 million upfront and up to $32.5 million for meeting certain targets. "ImmunoGen is eligible to receive up to $1.7 billion in potential target program exercise fees and milestone payments based on the achievement of pre-specified development, regulatory, and commercial milestones," the company said in a statement. It will also be eligible for certain tiered royalties as a percentage of worldwide sales. ImmunoGen shares have fallen 47% in the last 12 months, while the S&P 500 has gained 12%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Eli Lilly (LLY) was awarded a $1.08B firm-fixed-price contract for manufacture, distribution and storage of Bebtelovimab in support of the national emergency response to COVID-19

The FDA on Friday authorized Eli Lilly And Co''s (NYSE: LLY ) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized bebtelovimab for emergency use in patients with mild-to-moderate COVID-19 who are at high risk of progression to severe disease, including hospitalization or death. Bebtelovimab should be used when alternative COVID-19 treatment options approved or authorized by the FDA are not accessible … Full story available on Benzinga.com

The FDA authorised bebtelovimab for emergency use in patients with mild-to-moderate COVID-19 who are at high risk of progression to severe disease, including hospitalisation or death The post US FDA authorises Eli Lillys COVID-19 antibody drug appeared first on Express Pharma .

Late last month the Food and Drug Administration (FDA) revoked its emergency use authorization for Regenerons antibody drug, along with Eli Lillys version. The two medications had been the backbone of antibody treatment, and doctors were hard-pressed to come up with fallbacks when they didnt work against omicron. But now U.S. health regulators have authorized The post US Authorizes New Antibody Drug to Combat Omicron Variant appeared first on HillReporter.com .

Bebtelovimab wins emergency use authorization for Covid-19 Related Stocks: LLY , REGN , ABCL ,

The US Food and Drug Administration said it cleared the Eli Lilly drug for adults and adolescent patients with mild-to-moderate cases of Covid-19.The Biden administration purchased 600,000 doses before the authorization and will begin distribution of initial supplies to state health authorities

US FDA authorises Eli Lilly''s Covid-19 antibody drug to fight omicron

The Food and Drug Administration said it cleared the Eli Lilly drug for adults and adolescent patients with mild-to-moderate cases of COVID-19.

The FDA on Friday gave emergency authorization to a new monoclonal antibody drug that has been found to be potent against the omicron variant of the coronavirus. The post FDA clears COVID drug from Eli Lilly that shows promise against omicron appeared first on Boston.com .

it clears the Eli Lilly drug for adults and adolescent patients with mild-to-moderate cases of COVID-19.

The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness.

Eli Lilly has received FDA authorization for its new Omicron-effective monoclonal antibody drug weeks after its previous drug had its approval pulled for being ineffective against the strain.

The Food and Drug Administration on Friday granted emergency use authorization for a new monoclonal antibody drug to treat COVID-19.

Eli Lilly & Co. said late Friday that the U.S. Food and Drug Administration has issued an emergency-use authorization for bebtelovimab, the pharma company''s antibody treatment for COVID-19. Bebtelovimab now can be used for the treatment of mild-to-moderate COVID-19 in adults as well as children older than 12 years of age and over a certain weight who are at high risk of severe COVID-19 and for whom treatment options may be limited. Lilly announced late Thursday that the U.S. government had agreed to buy about 600,000 doses of bebtelovimab pending the EUA. Shares of Lilly were flat in the extended session after ending the regular trading day down 1.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.